Scienture (NASDAQ:SCNX – Get Free Report) and SCYNEXIS (NASDAQ:SCYX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.
Institutional and Insider Ownership
5.7% of Scienture shares are held by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are held by institutional investors. 21.4% of Scienture shares are held by insiders. Comparatively, 4.9% of SCYNEXIS shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Scienture and SCYNEXIS”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Scienture | $430,000.00 | 36.94 | -$41.51 million | ($2.51) | -0.16 |
| SCYNEXIS | $20.60 million | 1.52 | -$8.61 million | ($0.48) | -1.46 |
SCYNEXIS has higher revenue and earnings than Scienture. SCYNEXIS is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Scienture and SCYNEXIS’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Scienture | N/A | -56.28% | -44.76% |
| SCYNEXIS | -41.79% | -57.16% | -39.48% |
Risk and Volatility
Scienture has a beta of 3.32, meaning that its stock price is 232% more volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent recommendations and price targets for Scienture and SCYNEXIS, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Scienture | 1 | 0 | 1 | 0 | 2.00 |
| SCYNEXIS | 1 | 0 | 1 | 0 | 2.00 |
Scienture presently has a consensus target price of $1.50, suggesting a potential upside of 283.63%. SCYNEXIS has a consensus target price of $3.00, suggesting a potential upside of 328.02%. Given SCYNEXIS’s higher probable upside, analysts clearly believe SCYNEXIS is more favorable than Scienture.
About Scienture
Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.
About SCYNEXIS
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Receive News & Ratings for Scienture Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scienture and related companies with MarketBeat.com's FREE daily email newsletter.
